October 14th, 2024 | 07:00 CEST
Bayer, Vidac Pharma, Evotec – Enormous potential
Since the US Federal Reserve cut key interest rates and signaled a continuation of its loose monetary policy, the Nasdaq Biotech Index has been on an upward trajectory and has significantly outperformed the broader market in recent days. The correction of the past few months seems to be over in this sector, and the all-time high from August 2021 is within reach. In addition to rising share prices, the number of acquisitions is also increasing significantly, a sign of the undervaluation of many listed companies.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
BAYER AG NA O.N. | DE000BAY0017 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619 , EVOTEC SE INH O.N. | DE0005664809
Table of contents:
"[...] In summary, there are many different healing processes that make us very confident that our drug has the ability to help many millions of people with a wide variety of causes of nervous system damage. [...]" Bill Radvak, CEO, NervGen Pharma
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Vidac Pharma – Skyrocketing
One of the absolute high-flyers on the market is the London-based biopharmaceutical company Vidac Pharma, which is developing cancer drugs with a revolutionary approach. Their treatments aim to reverse the abnormal metabolism of cancer cells and are thus designed to stop the proliferation of cancer cells.
Since the end of May this year, the innovator, led by one of the founding fathers of the Israeli life sciences industry, Prof. Max Herzberg, has risen a whopping 416% to a new annual high of EUR 0.80. The recent sharp increase in volume was striking. While the average volume on a typical trading day was 30,000 shares, it exploded to almost 750,000 in the last three sessions.
According to analyst firm Sphene Capital, the recent rally is just the beginning of a major upward trend. In their latest study, they issued a "Buy" recommendation with a target price of EUR 4.90 after the publication of recent study results.
Vidac Pharma recently published further positive news after the Company had already presented promising results from its preclinical studies with the active ingredient VDA-1275 for the treatment of solid tumors in the summer. The United States Patent and Trademark Office (USPTO) has granted Vidac Pharma a patent for the mode of action of its oncology and onco-dermatological treatment candidates. This patent protects Vidac's newly developed chemical compounds that specifically detach the hexokinase 2 isozyme from the mitochondrial VDAC pores. The clinical studies conducted to date indicate that these compounds have the potential to effectively inhibit the growth of cancer cells.
Evotec – Bad omens
Evotec, a company active in pharmaceutical research, can only dream of such a stock performance. Since the beginning of the year, the Hamburg-based company has seen a substantial decline of almost 75% to EUR 5.64. Both the charts and analysts are sending somewhat skeptical signals. Deutsche Bank Research reiterated its "Sell" rating and target price of EUR 4.
The reasons for this lie in the expectation that the upcoming quarterly results of the pharmaceutical drug researcher, due on November 6, are likely to be weak. To meet the annual targets, a significantly better final quarter is needed. To achieve this, the expected savings and operational improvements are needed. A drastic signal was sent by the analyst firm Jefferies, which downgraded Evotec shares from USD 8.70 to USD 3.80. The investment recommendation was cut from "Buy" to "Hold".
From a chart perspective, Evotec's shares are approaching their low for the year of EUR 5.06. If this level is broken on a sustained basis, analysts' price targets are likely to be reached more quickly than expected.
Bayer – Downward trend
The chart of the pharmaceutical and agricultural giant Bayer currently looks similarly battered. After an interim rally pushing the stock above the EUR 30 mark at the beginning of October, investors pulled the rip cord again, which is also likely to push the price close to its yearly low of EUR 25 from July.
The reason for the interruption of the bear market rally was the continuing uncertainty regarding the glyphosate litigation. A jury at a state court in Philadelphia awarded a plaintiff, who attributes his cancer to the use of glyphosate-based weed killers, a total of USD 78 million in damages. Bayer intends to appeal the decision.
According to CEO Anderson, Bayer is still making good progress on the corporate restructuring. In an interview with the Frankfurter Allgemeine Sonntagszeitung, the Company leader said that the restructuring is already at 80 to 90%. This status was not expected until the fall of 2025.
The biotech sector is booming and the Nasdaq Biotech Index is heading for a new all-time high. Vidac Pharma, with its revolutionary cancer therapy, has already gained 400%, but analysts see even significantly higher price targets. Bayer and Evotec, on the other hand, are trading close to their yearly lows, which could spark new downside pressure.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.